Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause 2007;14:978-984.

Sedlak CA, Doheny MO, Estok PJ, Zeller RA, Winchell J. DXA, health beliefs, and osteoporosis prevention behaviors. J Aging Health 2007;19:742-756. Level of evidence: I.

Vlasiadis KZ, Skouteris CA, Velegrakis GA, et al. Mandibular radiomorphometric measurements as indicators of possible osteoporosis in postmenopausal women. Maturitas 2007;58:226-235. Level of evidence: III.

Glynn RJ, Ridker PM, Goldhaber SZ, Zee RYL, Buring JE. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women’s Health Study. Circulation 2007;116:1497-1503. Level of evidence: I.

Wingo PA, Austin H, Marchbanks PA, et al. Oral contraceptives and the risk of death from breast cancer. Obstet Gynecol 2007;110:793-800. Level of evidence: II-2.

Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17ß-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;110:771-779. Level of evidence: I.

Cayan F, Dilek U, Pata O, Dilek S. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. J Sex Med 2007. Level of evidence: II-2.

Wu O, Briggs A, Dutton S, et al. Uterine artery embolisation or hysterectomy for the treatment of symptomatic uterine fibroids: a cost-utility analysis of the HOPEFUL study. BJOG 2007;114:1352-1362. Level of evidence: II-2.

Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074-1083. Level of evidence: II-2.

Feng Y, Hong X, Wilker E, et al. Effects of age at menarche, reproductive years, and menopause on metabolic risk factors for cardiovascular diseases. Atherosclerosis 2007 Aug 3; [Epub ahead of print]. Level of evidence: II-3.